Mr. Martin Babler has served as our Chief Executive Officer since April 2011. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and lead the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1996, Mr. Babler was employed at Eli Lilly and Company, a pharmaceutical company, in a position focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO, and was a board member of ZS Pharma, Inc., a biotechnology company, until its sale to AstraZeneca Inc., a pharmaceutical company.

Mr. Babler holds a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.

Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.

Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.

Robert Bitterman founded Cutanea Life Sciences Inc. in September 2005 as its President, Chief Executive Officer, and Board Director. Mr. Bitterman has had an extensive and successful career in the pharmaceutical industry achieving various milestones, most notably, the sale of Cutanea to Maruho Company Ltd. in February 2012. Maruho is a privately-owned Japanese dermatology-focused pharmaceutical company which celebrated its 100th year anniversary in October of 2015. During his tenure he has successfully transacted two proprietary technology license agreements in addition to acquiring a third technology and two commercially ready-to-market products. These form the foundation of Cutanea’s development and commercial operations for future value creation.

Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 into 2004. Under his direction Dermik secured FDA approval for six NDA’s (New Product Approvals) and one PMA, a class 3 medical device. He also directed eight commercial product launches in the U.S. and several product launches in other international markets. Mr. Bitterman was also responsible for constructing and directing an operating joint venture in the People’s Republic of China. During his ten-year tenure at Dermik Laboratories he led his team in achieving average sales and EBITA growth of 21% and 24%, respectively. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. He has also held the position of President and Chief Executive Officer of Isolagen, Inc. from September 2004 until April 2005

Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine and is a member of the Philadelphia Business Leaders Network.

He also serves as a director on the Board of Directors of Rxi Pharmaceutical Corporation.

Patrick Burnett has served as our Chief Medical Officer since April 2018. Dr. Burnett was most recently at Sun Pharmaceuticals where he was Associate Vice President of Clinical Development from September 2015 to March 2018, with oversight of the dermatology and rheumatology pipeline. Prior to Sun, Dr. Burnett was at Novartis from 2010 to August 2015, most recently as Global Program Medical Director. He is a board-certified dermatologist and was a member of the medical faculty at Vanderbilt University Medical Center as an Assistant Professor of Dermatology from 2004 to 2010. Dr. Burnett holds an M.D. and Ph.D. in neuroscience from Johns Hopkins School of Medicine and a B.S. in Biology and Biochemistry from the University of Iowa.

Dr. Dubin has advised life sciences companies and investors for over 20 years and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. He leads the biopharmaceutical investment banking practice at Leerink Partners.

In 1996, Dr. Dubin founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, he merged MEDACorp into Leerink Partners and joined its board of directors and executive committee. He serves as a director for Olivo Labs.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer-reviewed publications and performed a National Institutes of Health training fellowship at the Harvard Skin Disease Research Center.

Dr. Bhushan Hardas joined Almirall as Executive Vice President of R&D, Chief Scientific Officer and a member of the Management Board. Bhushan has trained in Molecular biology and dermatology and received an MBA in health care management. He was trained in Kings College London and the University of Michigan and has over 20 years of professional experience in Pharmaceutical industry in Dermatology and Medical Aesthetics, including Merz Pharmaceuticals in the US, with his last position there as Senior VP and CSO North America and Global Head of R&D for Dermatology. He has served as Chief Medical Officer (Devices) and Global Head of R&D Dermatology and Medical Aesthetics for Allergan, based in Irvine, California. His has extensive experience and knowledge in dermatology and medical aesthetics towards generating new innovative projects as well as providing expert advice on potential business development opportunities and external innovation.

Greg Licholai, MD is on faculty at Yale University and is the Chief Medical Information Officer at PRA Health Sciences, a global drug development service firm. Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals and responsible for all research and development activities. Earlier he was founder and President of Elipdera, focused on rare genetic and metabolic diseases, and at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was director of Ventures and Business Development at Medtronic Neurological, where he was responsible for approval of a novel implantable device to treat pediatric dystonia.

He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals, was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health, performed research in molecular genetics at Yale University and worked in molecular oncology at Rockefeller University. He received a B.S. from Boston College, Pre-Medical studies at Columbia University, an M.D. from Yale Medical School and an M.B.A from Harvard Business School. He is on the advisory boards of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care, Yale Healthcare Conference and Yale Center for Biomedical Innovation and Technology and a lecturer at the Harvard Innovation Lab as well as Yale School of Management.

Lori joined Dermira in 2016 as Chief Commercial Officer and is responsible for developing and implementing the commercial strategy for Dermira's lead product candidates. In this role, Lori oversees the Market Access, Marketing, Sales, Lifecycle Management and Professional Relations functions at Dermira. Lori brings nearly 20 years of commercial experience to Dermira. Prior to joining Dermira, Lori spent 15 years in positions of increasing responsibility within the sales and marketing organization at Allergan Inc., most recently as Vice President, Sales & Marketing for the Urology business. She also served as a member of the Allergan Commercial Leadership Team and the Operational Leadership Team. In previous roles within Allergan, she served as Marketing Director for Allergan’s medical dermatology brands and also held senior-level positions on the ACZONE® and BOTOX® commercial teams. Lori began her career at Johnson & Johnson, Inc. as a pharmaceutical sales representative. Lori holds a B.A. in interdisciplinary studies from Virginia Tech and an M.B.A. from the Carlson School of Management of the University of Minnesota.

Raymond A. Miller is a partner and member of the Leadership Team of the Health Sciences Department of Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients' intellectual property. Mr. Miller is a former member of the firm's Executive Committee and was previously co-chair of the firm's Intellectual Property Department.

Mr. Miller's clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.

Mr. Miller's practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.

During his 17-year tenure, Allergan was transformed from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014 with most of the increase stemming from organic growth. Allergan’s market capitalization increased from $2.3 billion in 1998 to $72 billion when Allergan was acquired by Actavis in 2015. Subsequently, the company was renamed Allergan PLC. Dr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4). He has lived in 10 countries and worked in 7 countries ranging from the U.S. to Europe and Asia.

In 2006, Dr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree and an Honorary Degree in Medicine from the University of Edinburgh and a Master of Business Administration degree from the London Business School. He also has an Honorary Degree in Pharmaceutical Sciences from Chapman University in California. Dr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., a member of the Supervisory Board of Royal Philips in the Netherlands and Chairman of privately held Bioniz Therapeutics and a Director of privately held Rani Therapeutics. He is a Special Advisor to Sienna Biopharmaceuticals. He is Deputy Chairman of the Board of Governors of London Business School, a Trustee of the California Institute of Technology, President of the International Council of Ophthalmology Foundation and is also involved on the Boards of many of the other US and international eyecare charities.

Professor Riedemann is co-founder of InflaRx and has served as Chief Executive Officer since inception of the company in 2007. Under his leadership, InflaRx was funded by international investors in 4 financing series and the company successfully conducted its initial public offering at the US Nasdaq stock exchange in November 2017. Throughout the company history, Prof. Riedemann was and continues to be critically involved in the scientific developments of InflaRx leading anti-human complement C5a antibody technology. He received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998. He spent several years in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School in 2007 where he still holds an adjunct Professorship for Experimental Surgery. He is specialized as Intensive Care Physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He has served as member of the Scientific Advisory Board and the Board of Directors of two large scientific governmental funded research programs in Germany from 2012-2015. His research has been awarded with several national and international awards and he published over 50 original research articles in high ranked scientific journals. He is inventor on numerous internationally granted patents and patent applications in the complement space.

Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline's Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.

Mr. Smith is a corporate lawyer focusing on intellectual property transactions, venture financings and regulatory matters for life sciences companies and investors, is of counsel with Pepper Hamilton LLP, resident in the Pittsburgh office. Mr. Smith is a member of the firm's Health Sciences Department. Mr. Smith’s intellectual property-related work includes IP transactions, regulatory issues and licensing. His corporate practice is concentrated in the organization, financing and growth of life sciences companies, and he is an authority on the legal issues surrounding the use of human biological materials. He frequently speaks at universities and trade conferences on commercial development of tissue, cell and stem cell technologies.

Mr. Smith is active in a number of trade organizations and serves on the executive committee of the Tissue Engineering and Regenerative Medicine International Society. Mr. Smith is a graduate of Hamilton College (A.B. 1977) and American University, Washington College of Law (J.D. 1980). He is admitted to practice in Pennsylvania.

David Steinberg joined Jefferies as Managing Director and Senior Research Analyst covering the Specialty Pharmaceuticals sector in January 2014. Previously he was a Managing Director at Deutsche Bank (formerly Alex. Brown) for 15 years. David was one of the first analysts on Wall Street to identify Specialty Pharma as a major growth opportunity for the investment community. He has regularly been voted to the Institutional Investor "All American Research Team", including most recently in 2017. He has also been selected to the Wall Street Journal's "Best on the Street" survey for stock picking.

David's research on various topics within the global drug industry has been frequently referenced in such national publications as Barron's, The New York Times, and Fortune. David has been involved with numerous dermatology-/aesthetics-focused companies during his career. Selected companies he has covered include Aclaris, Allergan, Anacor, Collagenex, Medicis, Penederm, Perrigo, and Valeant.

David received a degree in Business Administration from Colby College and a Master of Business Administration from the Harvard Business School.

Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.

DDr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.

In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.

Steve Xu MD FAAD is a Medical Director of the Center for-Biointegrated Electronics at Northwestern University and Instructor in the Department of Dermatology at Northwestern’s Feinberg School of Medicine. He received his undergraduate degree in bioengineering from Rice University summa cum laude. He completed his medical training at Harvard Medical School with special honors as a Soros Fellow, and a Masters in Health Policy and Finance with Merit from The London School of Economics as a Marshall Scholar. Dr. Xu has authored more than 70 peer-reviewed publications and listed as an inventor on 13 granted and pending patents. He has developed several medical device technologies across multiple medical fields including dermatology, orthopedics, cardiology and patient non-adherence that have raised competitive funding from government grants and private investors and garnered coverage from CNN, Today Show, Forbes and The Huffington Post. One example of these innovations includes a battery-free, miniaturized UV dosimeter available exclusively through Apple. For his academic interests, Dr. Xu focuses on the role of FDA regulation on medical device innovation and the development of policies that facilitate breakthrough innovation in healthcare. His publications have appeared in The New England Journal of Medicine, Science Translational Medicine, Annals of Internal Medicine, and JAMA Internal Medicine garnering press attention from sources such as The New York Times, CNN, The Washington Post, and The Los Angeles Times. Dr. Xu is the founding chair of educational initiatives for Advancing Innovation in Dermatology and the Advancing Innovation in Dermatology’s Accelerator Fund, a not-for-profit organization catalyzing new product innovation in the field.

George D. Yancopoulos, MD, PhD, became the Scientific Founder and Chief Scientific Officer of Regeneron in 1989, alongside Founder and Chief Executive Office, Leonard Schleifer, MD, PhD. Dr. Yancopoulos also currently serves as President of Regeneron.

After graduating as valedictorian at both Bronx High School of Science and Columbia University, Dr. Yancopoulos received his MD and PhD in Biochemistry and Molecular Biophysics from Columbia University. Later at Columbia, he served with legendary geneticist Dr. Fred Alt as his first post-doctorate student, working in molecular immunology. Dr. Yancopoulos was pursuing a career in academia until he met Dr. Schleifer in the late 1980s and saw the potential to make a major impact on medicine through biotechnology.

Regeneron is now a leading biopharma company with more than 6,500 employees and facilities in the United States, Ireland and the United Kingdom. With a robust research and development engine and an unwavering commitment to its science-driven approach, Regeneron has produced six FDA-approved drugs, including DUPIXENT® (dupilumab) for moderate-to-severe atopic dermatitis. Dr. Yancopoulos and his team have discovered important new medicines for patients with serious diseases, including cancer, vision-threatening eye diseases and rheumatoid arthritis, while also building a robust homegrown pipeline of investigational treatments.

Dr. Yancopoulos is a principal inventor of Regeneron's foundational technologies for target discovery and drug development, such as its proprietary VelociGene® and VelocImmune® platforms. Regeneron is committed to continual innovations in the drug discovery and development processthrough the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people.

Dr. Yancopoulos is passionate about bringing his success in the sciences full circle, and is deeply committed to inspiring top talent to pursue scientific careers through STEM (Science, Technology, Engineering and Math) education programs. He plays an active role in Regeneron's STEM commitments, including the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science competition, formerly sponsored by Westinghouse and Intel.